News | September 08, 2011

First Pediatric Patient To Leave Hospital With Ventricular Assist Device

September 8, 2011 – SynCardia Systems, manufacturer of the SynCardia temporary Total Artificial Heart, announced that Texas Children's Hospital in Houston has discharged its first pediatric Total Artificial Heart patient to wait for a matching donor heart at home. On Aug. 31, 18-year-old Jordan Merecka left the hospital using the Freedom portable driver, a wearable power supply for his Total Artificial Heart.

"Having Jordan home again is the best gift in the world," said Suzanne Merecka, Jordan's mother. "The artificial heart was a blessing when he needed it desperately and his father and I are glad that Texas Children's could offer a life-saving option when things looked very grim. He still has a heart transplant in his future, but the artificial heart has helped him grow stronger. He will be ready when the time comes."

Jordan is participating in the U.S. Food and Drug Administration (FDA)-approved investigational device exemption (IDE) clinical study of the Freedom portable driver. Weighing 13.5 pounds, the Freedom driver is the first U.S. portable driver designed to power the Total Artificial Heart both inside and outside the hospital.

"When I get home, I hope to be able to go fishing in the ponds in my neighborhood, hang out with my friends again, just relax, sit in my favorite chair," said Jordan. "I'm going to enroll in college classes while I'm waiting at home for my transplant."

Jordan was born with multiple congenital heart defects, including his heart on the wrong side of his chest (dextrocardia) and his heart vessels backwards (corrected transposition of the great arteries). In April 2011, Jordan was admitted to the hospital after he progressed to end-stage biventricular failure while awaiting a heart transplant. In May, all of his organs began to fail and he was placed on a ventilator. To save Jordan's life, on May 22, his doctors performed the hospital’s first implant of the Total Artificial Heart.

"It was always our plan to move Jordan to the Freedom driver as soon as he was strong enough and had met all the protocol guidelines," said David L.S. Morales, M.D., pediatric cardiovascular surgeon at Texas Children's Heart Center and associate professor of surgery and pediatrics at Baylor College of Medicine (BCM), who implanted the Total Artificial Heart. "Jordan will gain a morale boost by being out of the hospital, enjoying a more active teen life as he waits for heart transplantation."

For more information: www.syncardia.com

 

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...